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Abstract
Background: Allergen exposure and air pollution are two risk factors for asthma development and airway
inflammation that have been examined extensively in isolation. The impact of combined allergen and diesel
exhaust exposure has received considerably less attention. Diesel exhaust (DE) is a major contributor to ambient
particulate matter (PM) air pollution, which can act as an adjuvant to immune responses and augment allergic
inflammation. We aimed to clarify whether DE increases allergen-induced inflammation and cellular immune
response in the airways of atopic human subjects.
Methods: Twelve atopic subjects were exposed to DE 300 μg.m−3 or filtered air for 2 h in a blinded crossover study
design with a four-week washout period between arms. One hour following either filtered air or DE exposure, subjects
were exposed to allergen or saline (vehicle control) via segmental challenge. Forty-eight hours post-allergen or control
exposure, bronchial biopsies were collected. The study design generated 4 different conditions: filtered air + saline
(FAS), DE + saline (DES), filtered air + allergen (FAA) and DE + allergen (DEA). Biopsies sections were immunostained
for tryptase, eosinophil cationic protein (ECP), neutrophil elastase (NE), CD138, CD4 and interleukin (IL)-4. The percent
positivity of positive cells were quantified in the bronchial submucosa.
Results: The percent positivity for tryptase expression and ECP expression remained unchanged in the bronchial
submucosa in all conditions. CD4 % positive staining in DEA (0.311 ± 0.060) was elevated relative to FAS (0.087 ± 0.018;
p = 0.035). IL-4 % positive staining in DEA (0.548 ± 0.143) was elevated relative to FAS (0.127 ± 0.062; p = 0.034).
CD138 % positive staining in DEA (0.120 ± 0.031) was elevated relative to FAS (0.017 ± 0.006; p = 0.015), DES
(0.044 ± 0.024; p = 0.040), and FAA (0.044 ± 0.008; p = 0.037). CD138 % positive staining in FAA (0.044 ± 0.008)
was elevated relative to FAS (0.017 ± 0.006; p = 0.049). NE percent positive staining in DEA (0.224 ± 0.047) was
elevated relative to FAS (0.045 ± 0.014; p = 0.031).
Conclusions: In vivo allergen and DE co-exposure results in elevated CD4, IL-4, CD138 and NE in the respiratory
submucosa of atopic subjects, while eosinophils and mast cells are not changed.
Trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01792232.
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Background
According to the World Health Organization (WHO),
7 million deaths were attributed to air pollution in
2012, representing 1 in 8 deaths worldwide and making
air pollution the biggest single environmental health risk
[1, 2]. The mortality was more than twice the 2008 esti-
mates, confirming that air pollution is increasingly taking
a toll on human health [2]. The WHO results are substan-
tiated by numerous epidemiological studies that have
established a significant association between exposure to
ambient air particulate matter (PM) and increases in mor-
tality and morbidity due to cardiovascular and respiratory
diseases [3–5].
Asthma is a major public health problem and it is esti-
mated that 300 million people suffer from asthma around
the globe, with 250,000 annual deaths and more than 2
million annual emergency room visits in the U.S. [6, 7].
Asthma is commonly defined as a chronic inflammatory
condition characterized by airway inflammation, reversible
airway obstruction, and increased airway responsive-
ness leading to symptoms such as wheezing, coughing,
shortness of breath, and chest tightness [8]. Airway
inflammation in asthmatic patients may stem from a
hypersensitivity of the respiratory tract to triggers like
allergens and air pollutants resulting in accumulation
of chronic inflammatory cells in the airway wall [9].
Specific cures for asthma remain elusive and therefore,
in order to develop new therapeutic strategies and in-
form health policy on air quality, we require a greater
understanding of the mechanisms behind how environ-
mental exposures can trigger asthma attacks [10].
Toxicological studies have shown that ambient airborne
PM can induce the production of cytokines and oxidants
that initiate airway inflammation [11]. PM may have direct
effects on the pulmonary system, including induction of
an inflammatory response, exacerbation of existing airway
disease or impairment of pulmonary defense mechanisms
[12]. Epidemiologic reports have indicated that there is a
higher prevalence of asthmatic and allergic symptoms in
people who live in close proximity to major roads relative
to those in more distant locations [13–15]. Diesel exhaust
(DE) is a main contributor to ambient PM air pollution
[16]. It has been suggested that exposure to DE can trigger
T-helper type 2 (Th2) immune responses which are directly
associated with the development and exacerbation of
allergic asthma [17]. Consistent with observational studies,
animal and human nasal models have demonstrated that
DE can act to augment allergic immune responses [18–21].
The chronic airway inflammation in allergic asthma is
characterized by activation of mast cells, type 2 innate
lymphoid cells (ILC2), T cells and infiltration of activated
eosinophils and basophils [22]. Inhalation of allergen,
results in Th2 cell activation and secretion of inflamma-
tory cytokines such as interleukin (IL)-4, IL-5, IL-9 and
IL-13, which are considered to play an important role in
the mucus hyper-secretion, thickening and contraction
of airway smooth muscle in atopic asthmatic patients
[22–25]. Asthma is a phenotypically heterogeneous dis-
order and, over the years, many different clinical sub-
types of asthma have been described [26] and classified
by trigger or symptoms such as allergic, non-allergic,
exercise-induced and cold-induced [27]. In our current
study, we have focused on classic allergic asthma, and
the study design and interpretation followed accordingly.
It has been hypothesized that environmental allergens
impose a greater effect in the presence of DE exhaust
but the exact mechanism behind this synergy is still not
clear. Our study investigated the impact of DE exposure
on allergen-induced airway inflammation as assessed in
the submucosa of bronchial biopsies. Our hypothesis
was that allergen exposure results in an increase in air-
way inflammation in the submucosa that was synergis-
tically increased with DE exposure. We used a blinded
crossover study design in atopic human subjects with
segmental allergen challenge following controlled expos-
ure to either filtered air or freshly generated DE. Our
results demonstrate that controlled allergen exposure
resulted in no increases in submucosa mast cells or
eosinophils, 48 h post-exposure, in either filtered air or
DE exposed conditions. In contrast, combination allergen
and DE exposure resulted in an increase in submucosa
CD4, IL-4, CD138 and NE relative to filtered air and
saline. Our results suggest a role for CD4+ and Th2 im-
mune responses in airway inflammation in response to
combination exposures that may not be observed in single
exposure studies in atopic subjects.
Results
Subject characteristics
Study subject gender, age, height, weight, body mass index
(BMI), forced expiratory volume in 1 s (FEV1), methacho-
line PC20, and allergen used for segmental allergen chal-
lenge are described in Table 1. The study involved samples
from 7 female subjects and 5 male subjects. Samples from
all 12 subjects were used for IL-4 immunostaining and
morphometric analysis. For tryptase, eosinophil cationic
protein (ECP), CD4, CD138 and neutrophil elastase (NE)
staining, two bronchial biopsies did not contain sufficient
submucosa area, resulting in only 10 subjects available for
comparison across the four experimental conditions for
these endpoints.
Submucosal changes within bronchial biopsies induced
by single exposure or co-exposure
Tryptase and ECP are unchanged by the combination of
diesel exhaust and allergen (DEA)
Analysis of tryptase-positive staining in bronchial mucosa
revealed distinct and strong granular cytoplasmic staining
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in cells with isolated observations of extracellular staining
(Fig. 1b). Quantification of the tryptase positively stained
pixels, demonstrated no differences between any experi-
mental conditions (Fig. 1c) although there was a trend to
increased staining in the DEA (diesel exhaust + allergen)
samples.
Analysis of ECP-positive staining in bronchial mucosa
revealed distinct cytoplasmic localization in cells with
pervasive observations of extracellular staining suggesting
eosinophil degranulation (Fig. 2b). Quantification of the
ECP-positive pixels, demonstrated no differences between
experimental conditions (Fig. 2c).
Neutrophil elastase is elevated by DEA
Analysis of NE-positive staining in bronchial mucosa
revealed distinct immunohistochemical localization of
elastase in neutrophils with no observations of extra-
cellular staining (Fig. 3b). Quantification of the NE-
Table 1 Subject characteristics
Subject Gender Age (years) Height (cm) Weight (kg) BMI FEV1 (% of pred) Methacholine PC20 (mg/mL) Positive SPT
1 F 20 158 54.6 22 104 13.85 HDM
2 F 31 173 70 24 113 >16 HDM
3a M 32 161 68 26 123 30.74 Pacific Grasses
4 F 34 157 55 22 79 0.23 Pacific Grasses
5 M 27 178 70 22 105 >128 HDM
6 F 25 173 73 25 117 >128 HDM
7a M 27 186 85 25 107 87.64 Pacific Grasses
8 F 46 165 65 24 63 >128 HDM
9a F 31 146 50 23 103 0.26 Birch
10 M 28 176 90 29 100 19.12 Pacific Grasses
11a M 23 169 83 29 104 2.41 Pacific Grasses
12 F 23 172 96 32 101 54.32 HDM
Mean (SD) 29 (7) 168 (11) 72 (15) 25 (3) 102 (16)
M male, F female, BMI body mass index, FEV1 forced expiratory volume in one second, % of pred percentage of predicted, PC20 provocative concentration causing
a 20 % fall in FEV1, SPT skin prick test, HDM house dust mite allergen
aPrevious smoker
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Fig. 1 Immunohistochemical staining of tryptase-positive mast cells in human bronchial submucosa tissue. a Representative 20X image of positive
staining using mAb AA1 for tryptase with positive staining in red with Mayer’s hematoxylin counterstain in blue from a subject exposed to FAA.
b Zoom region (40X) highlighted in panel a black box. c Positive pixel count quantification of submucosa region for tryptase staining. Data are
expressed as mean ± SEM. n = 10 for each experimental condition
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Fig. 2 Immunohistochemical staining of ECP-positive eosinophils in human bronchial submucosa tissue. a Representative 20X image of positive
staining using mAb EG2 for ECP with positive staining in red with Mayer’s hematoxylin counterstain in blue from a subject exposed to FAA.
b Zoom region (40X) highlighted in panel a black box. c Positive pixel count quantification of submucosa region for ECP staining. Data are
expressed as mean ± SEM. n =10 for each experimental condition
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Fig. 3 Immunohistochemical staining of elastase-positive neutrophils in human bronchial submucosa tissue. a Representative 20X image of posi-
tive staining using mAb NP57 for NE with positive staining in red with Mayer’s hematoxylin counterstain in blue from a subject exposed to FAA.
b Zoom region (40X) as highlighted in black box of panel a. c Positive pixel count quantification of submucosa region for NE staining. Data are
expressed as mean ± SEM. n = 10 for each experimental condition. *p < 0.05
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stained pixels demonstrated a significant increase (p =
0.031) in staining after DEA (0.224 ± 0.047) relative to
FAS (0.045 ± 0.014). There were no significant differ-
ences between FAS vs. DES (0.077 ± 0.024, p > 0.999)
or FAA (0.229 ± 0.069, p = 0.175) (Fig. 3c).
CD138 positive cells are elevated by FAA and DEA
Analysis of CD138-positive staining in bronchial mu-
cosa revealed distinct membrane staining in plasma
cells (Fig. 4b). Quantification of the CD138-positive pixels
demonstrated a significant increase in staining after DEA
(0.120 ± 0.031) relative to FAS (0.017 ± 0.006, p = 0.015),
DES (0.044 ± 0.024, p = 0.040), and FAA (0.044 ± 0.008,
p = 0.037). CD138 positive staining in FAA was elevated
relative to FAS (0.017 ± 0.006; p = 0.049) (Fig. 4c).
CD4 positive cells are significantly elevated by DEA
Analysis of CD4-positive staining in bronchial mucosa
revealed distinct membrane staining in T cells (Fig. 5b).
Quantification of the CD4-positive pixels demonstrated
a significant (p = 0.035) increase in staining after DEA
(0.311 ± 0.060) relative to FAS (filtered air + saline [control
(vehicle) for allergen]; 0.087 ± 0.018).
IL-4 expression is elevated by DEA
Analysis of IL-4-positive staining in bronchial mucosa
revealed distinct immunohistochemical localization of IL-4
in cells with no observations of extracellular staining
(Fig. 6b). Quantification of the IL-4-stained pixels, dem-
onstrated a significant increase (p = 0.034) in staining
for DEA samples (0.548 ± 0.143) relative to FAS sam-
ples (0.127 ± 0.062). There were no significant differ-
ences between FAS vs. DES (0.353 ± 0.088, p = 0.086)
or FAA (0.426 ± 0.130, p = 0.150).
Finally, Pearson correlation coefficients matrix was
performed for each of the endpoints versus each other
(Additional file 1: Tables S1 and S2). No endpoints were
significantly correlated under DEA, suggesting potential
distinctive biology associated with the endpoints induced
by DEA. NE and CD138 were positively correlated (r =
0.76, p < 0.01) after DES. After FAA, tryptase and CD138
were positively correlated (r = 0.64, p < 0.04) and ECP and
IL-4 were also positively correlated (r = 0.61, p < 0.05).
Discussion
To our knowledge this is the first blinded crossover
human study using controlled exposures to a combin-
ation of DE and allergens to investigate the lower airway
inflammatory responses in bronchial biopsies in atopic
individuals. Considerable evidence suggests that that the
effects of DE and allergens are synergistic [28]. We
provide further evidence for synergy by demonstrating
that a combination of DE and allergen (but not DE or
allergen alone) results in augmented CD4, IL-4, NE and
CD138. Our results suggest that studies examining aller-
gen or air pollution in isolation, including those related
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Fig. 4 Immunohistochemical staining of CD138-positive plasma cells in human bronchial submucosa tissue. a Representative 20X image of posi-
tive staining using mAb B-A38 for CD138 with positive staining in red with Mayer’s hematoxylin counterstain in blue from a subject exposed to
FAA. b Zoom region (40X) highlighted in black box of panel a. c Positive pixel count quantification of submucosa region for CD138 staining. Data
are expressed as mean ± SEM. n = 9 for each experimental condition. *p < 0.05; **p < 0.01
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Fig. 6 Immunohistochemical staining of IL-4-positive cells in human bronchial submucosa tissue. a Representative 20X image of positive staining
using mAb 4D9 for IL-4 with positive staining in red with Mayer’s hematoxylin counterstain in blue from a subject exposed to FAA. b Zoom re-
gion (40X) highlighted in black box of panel a. c Positive pixel count quantification of submucosa region for IL-4 staining. Data are expressed
as mean ± SEM. n = 12 for each experimental condition. *p < 0.05
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Fig. 5 Immunohistochemical staining of CD4-positive T cells in human bronchial submucosa tissue. a Representative 20X image of positive stain-
ing using mAb 4B12 for CD4 with positive staining in red with Mayer’s hematoxylin counterstain in blue from a subject exposed to FAA.
b Zoom region (40X) highlighted in black box of panel a. c Positive pixel count quantification of submucosa region for CD4 staining. Data are
expressed as mean ± SEM. n = 10 for each experimental condition. *p < 0.05
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to drug development, may underestimate the real-world
impact of heterogeneous environmental exposures on
airway inflammation in atopic humans [29–31]. Our
results have implications for health policy aimed at pro-
tecting air quality for vulnerable populations [32], recog-
nizing that the concentration of DE 300 μg.m−3 used in
our study is most relevant in the context of occupational
exposure in Western countries or the daily average level
of PM in some developing countries in the world such
as China and India [33, 34].
Mast cells are known to participate in allergic inflam-
mation [35]. Previous studies have shown increases the
number of mast cells in healthy volunteers at 6 h [36]
and 18 h [37] after exposure to DE. Tryptase is the most
plentiful granule constituent in mature and activated
mast cells [38], thus we stained for tryptase as it is a
reliable biomarker of mast cell presence and activation.
Basophils are the only other cell type that express tryp-
tase, but their frequency is known to be considerably
lower than that of in mast cells [39] and tryptase levels
in human basophils are less than 1 % of those in tissue
mast cells [40]. Our results demonstrate that 48 h fol-
lowing co-exposure to DE and allergen, there was no
elevations in tryptase positive cells in the submucosa.
Eosinophils are another pro-inflammatory white blood
cell type that differentiates from myeloid progenitors in
the bone marrow; mature eosinophils travel through
blood vessels to mucosal surfaces throughout the body
[41]. We examined ECP as a selective marker for eosino-
phils, as this protein is largely restricted to these cells;
there is evidence that ECP can be detected in neutro-
phils [42, 43], but rarely and weakly [44]. Staining ECP
(rather than MBP or EPO) as a markers of intensity of
eosinophilic inflammation of the airways in allergic dis-
eases [45], allowed us to compare our results with other
DE controlled exposure studies [46, 47].
Our data demonstrate that in atopic individuals, com-
bination exposure (DE followed by allergen) does not
impact ECP expression in bronchial submucosa. This is
consistent with a previous controlled DE exposure study
that showed no significant increase in the count of tissue
eosinophils at 18 h post-exposure [37], although studies
examining bronchoalveolar lavage [48] and induced spu-
tum [47] have shown increases at 6 h post-exposure.
We chose a later time point 48 h for sampling tissue
biopsies, thus there is potential that early inflammatory
cell recruitment and activation was missed due to reso-
lution of the inflammatory event. A previous study utiliz-
ing segmental allergen challenge was aimed to elucidate
the time course of inflammatory events in allergic airway
diseases. They have shown that the level of tryptase in
BAL increases immediately within 12 min following the
segmental allergen broncho-provocation with ragweed in
allergic rhinitis patients, but this signal was resolved by
48 h. In contrast, ECP levels were only increased at the
late time point [49]. This leads us to speculate that in our
tissue biopsies, ECP was released from the tissue eosino-
phils and by 48 h was measureable only in BAL [50].
Neutrophilic inflammation is associated with progres-
sion and the development of chronic respiratory diseases,
such as severe asthma [51]. Neutrophils are granulocytes
and one of the first responders to the environmental
insults and migrate to the site. In neutrophils, neutrophil
elastase (NE) contributes mainly to digestion of ingested
foreign particles, chemotaxis, infiltration and tissue re-
modeling by degrading connective tissue proteins such
as elastin and collagens [52]. Exposure to DEP is as-
sociated with accumulation of neutrophils and it has
been shown that DEP can activate neutrophils and
augment the expression of NE and other mediators of
tissue destruction [53, 54].
We demonstrate that NE expression is increased by
DEA, suggesting neutrophilic inflammation is induced
by the combined exposure to DE and allergen. Our data
are consistent with our own study of combined exposure
[50], in which BAL neutrophils were increased by DE
plus allergen, but contrast somewhat with previous hu-
man controlled studies that reported increased neutro-
phils associated with DE in various compartments at
multiple timepoints through 24 h post-exposure [55],
since we showed so similar effect (assessing DES alone)
at 48 h.
CD138 (syndecan-1) is a cell surface proteoglycan and
predominantly is expressed on mature plasma cells and
weakly in epithelial cells. CD138 is highly sensitive and
specific marker for identification of plasma cells and plasma
cell differentiation. CD138 modulates cell growth, differen-
tiation, adhesion and migration, thus plays important roles
in the regulation of inflammatory responses [56].
Aggregation of CD138+ plasma cells were identified in
pulmonary fibrosis [57] and in the lung submucosa of
severe asthmatics with increased inflammatory lympho-
cytes infiltrates [58]. Increased frequencies of CD138+
IgE+ cells were detected in the lamina propria of the
nasal mucosal biopsies from allergic patients [59]. Also
the number of CD138+ IgE+ cells was positively corre-
lated with the IgE serum titres in atopic individuals [60].
Exposure to environmental allergens triggers Th2 cells
differentiation and production of IL-4 and IL-13 which
proliferate and differentiate B cells into plasma cells and
switch to IgE synthesis [61]. It has been shown that
inhalation allergen challenge significantly increases the
number of CD138+ IgE-secreting cells in murine lungs
[62]. CD138 immunostaining is proven to be an excel-
lent indicative of IgE+ cells in the lung tissue [63]. CD138+
cells were detectable in bronchial biopsies at 24 h but
not in BAL after segmental allergen challenge in atopic
asthmatics [64].
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We demonstrate that CD138 expression is increased
in DEA vs. FAS, DES and FAA, suggesting plasmacytosis
is induced by DE added to allergen. CD138 expression
in FAA was elevated relative to FAS, suggesting the
effect of allergen challenge in submucosal plasmacytosis.
Our data are consistent with a previous human nasal
model that have confirmed that co-administration of DE
particles and allergen stimulate an increase in level of
allergen specific IgE in nasal lavage samples [21] and a
trend in our own study of BAL from DE-allergen co-
exposure [50].
CD4+ T-cells play an essential role in adaptive allergic
immune responses. CD4 is a transmembrane glycopro-
tein selectively expressed on the surface of helper T-cells
and plays an important role in the regulation of T-cell
signalling and its functional consequences [65]. Follow-
ing activation, naive CD4+ T-cells differentiate into one
of the sub-types of T-helper cells: Th1 [66], Th2 [67],
Th9 [68], Th17 [69], or Th22 [70], depending on the
nature of antigen and the cytokines present in the sur-
rounding milieu [71]. Th2 cells secrete IL-4, IL-5, IL-6,
IL-9, IL-10 and IL-13 and induce eosinophil activation
and differentiation; Th2 cells are more proficient B-cell
helpers and can stimulate IgG1 and IgE production.
Thus, they are well positioned to play substantial role in
the pathogenesis of allergic inflammation. In the present
work, we explored whether co-exposure to DE and aller-
gen induced recruitment of CD4+ cells in human lung
tissue. We demonstrate that the number of CD4+ cells
significantly increased only in DEA vs. FAS (p = 0.035),
which suggest an interaction between DE and allergen.
In a single exposure model in healthy subjects, it has
been previously argued that DE does not alter the
number of CD3+, CD4+ and CD8+ lymphocytes in the
bronchial tissue at 18 h post-exposure [72].
IL-4 is known to be an important cytokine in the
development of allergic inflammation; it provides the
first signal that initiates B-cell class switching to IgE
production [73]. IL-4 can further enhance IgE-mediated
immune responses by up-regulating the expression of
low-affinity IgE receptor (FcεRII/CD23) on B-lymphocytes
and macrophages and the high-affinity IgE receptor
(FcεRI) on mast cells [74, 75]. IL-4 induces the differenti-
ation of naive T lymphocytes into Th2 cells which secrete
more IL-4, IL-5, and IL-13, maintaining a suitable envir-
onment for further Th2 cells differentiation [76, 77]. IL-4
can also stimulate the expression of vascular cell adhesion
molecule-1 (VCAM-1) on endothelial cells, which leads to
enhanced migration of T-cells, eosinophils, macrophages
and mast cells to inflamed tissue [78]. To for Th2 cells but
IL-4 is a signature cytokine of type 2 immunity. IL-4 is
known as a positive feedback cytokine for Th2 cell differ-
entiation that stimulates the differentiation of naive
CD4+ cells into IL-4-secreting Th2 cells [79, 80]. It has
been shown that human mast cells are one of the
major sources of IL-4 in the skin, nasal and bronchial
tissue [81–83]. IL-4 is able to induce the development
of Th2 cells; thus, this stored and preformed IL-4
within mast cell granules has an important influence
during the initiation and maintenance of the allergic
immunological response. Basophils [84], naive T cells
[85] and innate lymphoid cells [86] are also immediate
source of IL-4 upstream of Th2 cells differentiation. IL-4
contributes to airway obstruction in asthma via the induc-
tion of mucus hypersecretion in mice and human cell
lines, and increases the release of several pro-inflammatory
cytokines such as IL-6, GM-CSF and eotaxin from human
lung fibroblasts [87]. IL-4 is a major factor in the recruit-
ment and activation of inflammatory cells that may contrib-
ute to inflammation and lung remodeling in chronic
asthma [88].
We demonstrate that IL-4 expression is increased in
DEA vs. FAS (p = 0.034), suggesting a Th2 immune re-
sponse is induced by DE and allergen that is not observed
with isolated (single) exposures. Our data are consistent
with in vivo animal, in vitro, and human studies that have
confirmed DE has strong pro-Th2 effect [89, 90]. Human
nasal challenge studies have shown that co-administration
of DE particles and allergen stimulate a Th2 immune re-
sponse in nasal wash samples 4 days post-challenge [21,
91, 92]. There is one conflicting study that has shown no
differences in expression of IL-4 in the bronchial sub-
mucosa but its authors mention that the bronchial tissue
in their study was assessed at a single time point 6 h post-
DE exposure [93] while most of the cytokine changes ob-
served in previous human nasal studies and animal expos-
ure studies were found 24 to 48 h post-exposure [94]. A
previous study also evaluated the effects of diesel exhaust
inhalation in enhancing allergic immunologic responses in
lower airways [95]. Consistent with our results, they simi-
larly found an increase in the IL-4 level (by 1.7-fold, which
was close to statistical significance); they also found a
non-significant elevation in the number of eosinophils in
induced sputum due to DE exposure. However, there
are some fundamental differences between their model
and our current study a) their allergen challenge was per-
formed by inhalation but we challenged our subjects seg-
mentally, with saline control simultaneously, which confers
some advantages and limitations; b) the diesel exhaust con-
centration that we used was ~300 μg.m−3 PM2.5 while
theirs was ~100 μg.m−3; c) they analyzed sputum and
blood that were acquired 22 h post-exposure while we ana-
lyzed endobronchial biopsies that were obtained 48 h post-
exposure.
A primary strength of our study is that it is a double-
blinded cross-over study that fundamentally eliminates
typical confounding covariates, since each subject serves
as his/her own control. Our study does have limitations,
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however. One limitation is generalizability. For example,
given the specific gap (one hour) between inhalation
exposure and segmental allergen, it is difficult to know
whether similar findings would occur with simultaneous
exposure or some other gap, but we effectively consider
this “co-exposure” given that the particles from DE will
remain in the airways for hours after inhalation and thus
then be present when the allergen is inhaled (though,
admittedly, the exact dynamics therein are unknown
and an important future direction for our work). An-
other concern is whether airway changes relevant to
our hypotheses can be induced by the bronchoscopy
procedure itself. Investigative bronchoscopy and bron-
chial provocation challenge are commonly used tech-
niques in airway inflammation research [96]. While FEV1
and PEFR dropped due to bronchoscopy with lavage and
biopsies, both returned to baseline within 2 to 24 h
[97, 98]. Accordingly, we doubt that significant inflam-
mation from these procedures persists through 48 h.
Conclusions
In summary, we have demonstrated for the first time
that acute exposure to DE followed by segmental aller-
gen challenge increases the submucosal recruitment of
CD4 cells, CD138-positive plasma cells and expression
of neutrophil elastase and IL-4 in the submucosa of atopic
human subjects. Our study design and results suggest that
experimental data from complex exposures can capture
real-world exposures that enlighten our understanding of
biology and maybe inform those concerned with public
health and policy based on complex exposures.
Methods
Subject recruitment
Twelve atopic subjects (19–49 years old) were screened,
informed of the protocol, procedures, and potential risk,
and agreed to participate in the study (ClinicalTrials.gov
identifier: NCT01792232). The UBC Research Ethics Board
approved the study protocol and informed consent form.
Allergic sensitization to house dust mite (HDM), birch and
Pacific grasses were diagnosed by skin prick test. Birch-
sensitive subjects were not studied in the birch season
(February-April) and grass-sensitive subjects were not stud-
ied in the Pacific grasses season (May-August). Subject
characteristics are described in Table 1.
Exposure protocol
Each subject was exposed for 120 min to filtered air
(FA; the control for diesel exhaust) or freshly gener-
ated diesel exhaust (DE PM2.5 300 μg.m
−3; Table 2) in
a double-blinded crossover experiment, with the two dis-
tinct visits randomized and counter-balanced to order,
with a four-week washout period between each condition
(Fig. 7). In this study design, each subject serves as his/her
own control.
During the two-hour exposure, the subject was asked
to exercise on a bicycle ergometer for a total of 30 min
(2 × 15 min at ~60 rpm cadence and ~25 W of resist-
ance) to increase ventilation-heart rate and mimic modest
intermittent activity.
Bronchoscopy procedure
Segmental allergen challenge (Bronchoscopy #1)
One hour following each exposure to DE or FA, segmen-
tal allergen challenge was performed through standard
fiberoptic bronchoscopy procedure. Bronchoscopy was
used to deliver a diluent-controlled solution of the positive
skin prick allergen extract, at a concentration 10-fold
lower than the dose producing a positive wheal ≥3 mm,
into a right lower lobe segment. A 5 mL diluent control
was delivered into a left lower lobe segment.
Endobronchial biopsies (Bronchoscopy #2)
The second bronchoscopy was done 48 h post-allergen
challenge, endobronchial biopsy specimens (size ≤2 mm)
were obtained from the same segments exposed to aller-
gen or saline.
Following an approximately 1 month washout period,
subjects returned and received the second two-hour ex-
posure, followed by a bronchoscopy during which aller-
gen and saline were administered to opposite lungs and
different segments than those during the first exposure.
Thus, endobronchial biopsies for each of the 4 different
crossover conditions was created: 1) FAS: filtered air +
saline, 2) DES: DE + saline, 3) FAA: filtered air + allergen
and 4) DEA: DE + allergen.
Bronchial biopsies processing
The endobronchial biopsies were immediately added to ice-
cold acetone containing the protease inhibitors iodoaceta-
mide (20 mM) and phenylmethylsulfonylfluoride (PMSF;
2 mM, Sigma, Oakville, ON) and fixed at −20 °C overnight
(16–24 h). The next day, biopsies were transferred to fresh
Table 2 Inhaled exposure characteristics
Condition PM2.5 (μg/m
3) Particle number (#/cm3) CO (ppm) NO (ppb) NOx (ppb) NO2 (ppb) NO2/PM# (μg/#)
FA 8.2 (6.9) 1750.4 (235.1) 2.8 (0.1) 25.3 (5.0) 71.1 (9.8) 45.9 (7.7) 4.9 × 10−9
DE 302.0 (30.5) 5.4 × 105 (6.4 × 104) 14.1 (2.0) 8665.5 (1287.1) 9185.3 (1366.1) 519.7 (118.6) 1.8 × 10−9
Values are presented as mean (SD)
FA filtered air, DE diesel exhaust
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acetone and then to methyl benzoate (Sigma, Oakville,
ON) for 15 min each at room temperature, before infiltra-
tion with glycol methacrylate (GMA) resin as previously
described at Britten et al. [99].
Glycol methacrylate acrylic resin (GMA) embedding
Glycol methacrylate acrylic resin (GMA) is a hydrophilic
plastic resin which provides a number of advantages
over frozen and paraffin-embedding techniques [100].
The JB-4 Embedding Kit (Polysciences, Warrington, PA)
was used for embedding in GMA with some modifica-
tion to its original manufacturer’s instructions described
in details at Wilson et al. [100]. For polymerization of
GMA resin, benzoyl peroxide was added to the airtight
embedding capsule containing tissue sample and kept
for 48 h at 4 °C to increase polymerization of GMA. The
polymerized resin block was stored desiccated at −20 °C
freezer until used for IHC staining.
Biopsy quality evaluation
GMA blocks containing each biopsy were removed from
embedding capsules and excess resin trimmed to form a
trapezium shape around the tissue. Sections were cut at
2 μm using an ultra-microtome (Leica EM UC6 at JHRC
Histology lab) and floated on distilled water (dH2O) and
picked up onto 10 % poly-l-lysine (PLL)-coated slides
(Fisher Scientific, Ottawa, ON). Slides were left on a hot
plate to completely dry out, followed by addition of one
drop of toluidine blue stain for 2 min following by
drying and mounting in DPX (Sigma, Oakville, ON) for
subsequent examination under light microscope to check
biopsy quality. In order to qualify for immunohistochemi-
cal analysis the tissue section must have a minimum of
0.46 mm2 of submucosal tissue (lamina propria), exclud-
ing smooth muscle and glands [101]. If the section was
found to be of poor standard, further sections were cut
and reassessed. If no such level with acceptable histo-
logical standard was found in the biopsy, then the biopsy
was excluded from further IHC analysis.
Controls for Immunohistochemistry
Tonsil tissue samples removed from patients (kindly pro-
vided by Dr. Andrew Thamboo, Dept. of Otolaryngology
(ENT) at St. Paul's Hospital) were used as positive control
and staining with isotype-matched controls was used as
negative control (Additional file 2: Figure S1). Endogenous
peroxidase was blocked with a 100 μl of 30 % H2O2 solu-
tion in 10 mL of sodium azide and endogenous avidin and
biotin were blocked using a commercially available kit
from Vector Labs (Vector Laboratories, Burlington, On-
tario). Colour was developed using a VECTASTAIN
Elite ABC Kit (Vector Laboratories, Burlington,
Ontario).
Immunohistochemistry (IHC) on endobronchial biopsies
IHC was used to determine the number of CD4+, IL-4+
cells, CD138+ plasma cells, elastase-positive (NE+) neutro-
phils and activated (EG2+) eosinophils and tryptase-positive
(AA1+) mast cells in the lamina propria in endobronchial
biopsies (Table 3).
0 h 2 h 3 h
DE (300 µg.m-3 of PM 2.5) or FA   
inhalation
Bronchoscopy #2Bronchoscopy #1
48 h
Segmental allergen instillation Endobronchial biopsies
Fig. 7 Schematic of exposure protocol. Study subjects were exposed to DE (300 μg.m−3 of PM2.5) or FA (filtered air) for 2 h. One hour post-
exposure, a segmental allergen challenge was performed with allergen or saline vehicle in the right upper and middle lobe or left lingular lobe.
Forty-eight hours post-exposure endobronchial biopsies were obtained via bronchoscopy. The process was repeated following a washout period
of 1 month with exposure conditions reversed compared to the first visit
Table 3 Percent positivity for inflammatory biomarkers’ expression in the lung submucosa. Data are expressed as mean ± standard
error of the mean (SEM)
Exposure condition AA1 ECP NE CD138 CD4 IL-4
FAS 0.460 ± 0.053 0.308 ± 0.102 0.045 ± 0.014 0.017 ± 0.006 0.045 ± 0.014 0.127 ± 0.062
DES 0.681 ± 0.153 0.471 ± 0.175 0.077 ± 0.024 0.044 ± 0.024 0.045 ± 0.014 0.353 ± 0.088
FAA 0.646 ± 0.128 0.553 ± 0.109 0.229 ± 0.069 0.044 ± 0.008* 0.045 ± 0.014 0.426 ± 0.130
DEA 0.738 ± 0.159 0.487 ± 0.201 0.224 ± 0.047* 0.120 ± 0.031*, **, *** 0.045 ± 0.014* 0.548 ± 0.143*
FAS filtered air + saline, DES DE + saline, FAA filtered air + allergen, DEA DE + allergen, AA1 tryptase, ECP eosinophil cationic protein, NE neutrophil elastase
*p < 0.05, compared with FAS; **p < 0.05, compared with DES; ***p < 0.05, compared with DEA
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Semi-thin sections were cut at 2 μm from endo-
bronchial biopsies and immunostained with monoclo-
nal primary antibodies (Table 4). The immunostaining
procedure followed has been described previously [100].
Briefly, endogenous peroxidase was blocked using a 100 μl
of 30 % H2O2 solution in 10 mL of sodium azide and
endogenous biotin were blocked using a commercially
available kit from Vector Labs (Vector Laboratories,
Burlington, Ontario). Mouse anti-human monoclonal
antibodies were applied at appropriate dilutions (Table 4)
and incubated with coverslip 20–22 h at room temperature.
After washing with Tris-buffered saline (TBS, 3 × 5 min),
the sections were incubated with the biotinylated rabbit
anti-mouse secondary antibody (Dako, Burlington, Ontario)
for 2 h. ABC (avidin-biotin complex) kit (Vector La-
boratories, Burlington, Ontario) was applied after fur-
ther washing with TBS (3 × 5 min), and incubated for
2 h. The positive staining were then visualized using
AEC (3-amino-9-ethylcarbazole) chromogen kit (Bio-
Genex, Fremont, CA) and counterstained with Mayer's
Hematoxylin (Dako, Burlington, Ontario).
Quantification of Immunohistochemistry
IHC slides were scanned by Aperio ScanScope XT
(Aperio Technologies, Vista, CA) at 40X magnifica-
tion. Morphometric and immunohistochemical analysis
were performed on the digital images (0.25 μm/pixel)
using Aperio® ImageScope™ (version 11.2.0.780). The in-
corporated Positive Pixel Count (PPC) algorithm (version
9.1) was used to quantify inflammatory cells that stained
positive (positive pixels) for each antibody of interest. To
quantify positive pixels, a hue value of 0.0 (red) and hue
width of 0.5 was used, and all the three intensity ranges
(weak, positive, and strong) of staining were considered as
positive (Fig. 8). The number of positive pixels was divided
by the total number of pixels (positive and negative) in the
analyzed area, and multiplied by 100, to calculate the
percentage of positive pixels.
Numberof Positivepixels
Totalnumberof PositivepixelsþNegativepixels 100 %Positivityð Þ
For tryptase, ECP, NE, CD138, CD4 and IL-4, the
amount of a positive stain in an image and the area of
the submucosa were measured. The positive pixel counts
were expressed as percent (%) positive pixel/mm2 in the
submucosa.
Statistical analysis
One-way repeated measures ANOVA with Bonferroni
multiple comparison post hoc tests and Pearson correl-
ation coefficients matrix were performed using Graph-
Pad Prism® 6 software (GraphPad Software Inc., La Jolla,
CA). Combined Robust regression and Outlier removal
method (ROUT test) was used and an outlier in CD138
dataset was identified and removed. A p-value of <0.05
was considered statistically significant. Error bars shown
represent the standard error of mean (±SEM).
Table 4 List of primary monoclonal antibodies are used for IHC staining
Antibody Marker Cell Concentration (μg.mL−1) Catalog no. Source
AA1 Tryptase Mast cells 0.1 ab2378 Abcam Inc., Toronto, ON
EG2 (614) ECP Eosinophils 0.07 514-121 Diagnostics, Uppsala, SW
IL-4 (4D9) IL-4 Th2, mast cells 20.0 211-44-134AX Amsbio, Cambridge, UK
CD4 (4B12) CD4 Helper T cells 8.0 M731001-2 Dako, Burlington, ON
CD138 (B-A38) Syndecan-1 Plasma cells 1.0 MCA2459GA AbD Serotec, Raleigh, NC
NE (NP57) Elastase 2 Neutrophils 0.1 M075201-2 Dako, Burlington, ON
BA
Fig. 8 Demonstration of image analysis using Aperio® ImageScope™ software. A positive pixel count algorithm was used to quantify positive
staining in the submucosa (blue region) of bronchial biopsies for tryptase, ECP, NE, CD138, CD4, and IL-4. The airway epithelium was not examined
and positive staining in the epithelium was excluded from analysis. a Representative image of tryptase positive staining from a subject exposed
to FAA, Black arrows denote positive staining in submucosa area that are selected by the positive pixel count. b Image from a with submucosa
region selected by manual trace followed by positive pixel count recognition of tryptase stain (red colour) within submucosa region (blue colour)
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Additional files
Additional file 1: Tables S1 and S2. Pearson correlation coefficients
matrix for inflammatory biomarkers’ expression in the lung submucosa
after single or co-exposure to diesel exhaust and allergen. (PDF 213 kb)
Additional file 2: Figure S1. Immunohistochemical staining of positive
and negative controls. A) Representative 40X image of positive staining
using mAb AA1 for tryptase in human tonsil tissue; B) Representative 40X
image of positive staining using mAb EG2 for ECP in human tonsil tissue;
C) Representative 40X image of positive staining using mAb NP57 for
neutrophil elastase in human tonsil tissue; D) Representative 40X image
of positive staining using mAb B-A38 for CD138 in human lung tissue;
E) Representative 40X image of positive staining using mAb 4B12 for CD4
in human tonsil tissue; F) Representative 40X image of positive staining
using mAb 4D9 for IL-4 in human tonsil tissue; G) Representative 40X
image of isotype control using mAb mouse IgG1 (0.07 μg.mL−1) in
human lung tissue; H) Representative 40X image of isotype control
staining using mAb mouse IgG1 (20.0 μg.mL−1) in human lung tissue.
(PDF 482 kb)
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DEA: diesel exhaust and allergen; DES: diesel exhaust and saline;
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